111111111111111111111111111111111111111111111111111111111111111111111111111111111
Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development
Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October. In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products. Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing. More
New Unit Inaugurated at Egis’s Körmend Plant
Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.
Environment Protection - Electric Cars in the Egis Fleet
It is important for us to protect the future of our planet, therefore we try to reduce our ecological footprint. Egis uses more and more electric cars in its fleet in order to minimize the harmful substance output.
Active Agent Production Renewed
By renewing our active agent base, we wish to simultaneously raise the rate of our active agents produced internally in a reliable quality and at a competitive price as well as to increase our exports.
Other channels
Egis' products are sold to 100 countries.
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
Healthcare and sharing knowledge are in the heart of our CSR activities
Our highlighted past and future events you shouldn't miss
Quick news
Your browser is out of date. Please, use an updated version!